Back to Menu
1. Clinical presentation assessment
Common manifestations include jaundice, pruritus, clay-colored stools, right upper quadrant pain, and weight loss; alkaline phosphatase is often elevated in advanced disease.
2. Serologic testing
Liver function tests may show elevated bilirubin. CA19-9 and CEA are basic screening markers, and emerging biomarkers are under investigation.
3. Ultrasonography
Ultrasound is the first-line screening tool, demonstrating bile duct dilatation and obstruction. It can guide biopsy, but may be limited by bowel gas.
4. CT and MRI
Contrast-enhanced CT evaluates local invasion. MRI with MRCP noninvasively visualizes the biliary tree and supports staging and treatment planning.
5. Direct cholangiography
PTC delineates intrahepatic bile ducts, whereas ERCP visualizes distal ducts. Tissue sampling for histopathology can be obtained, and combined approaches improve diagnostic yield.
6. Endoscopic ultrasonography
EUS provides high-resolution imaging of the bile duct and enables EUS-guided fine-needle aspiration/biopsy to improve diagnostic accuracy for early lesions.
7. Molecular biomarker testing
Alterations such as FGFR2 and IDH1/2 are relatively common and may serve as therapeutic targets; liquid biopsy offers an emerging direction.
8. Pathological examination
Histopathology is the gold standard. Intraoperative frozen section can confirm negative margins, and tumors are classified by degree of differentiation.
Jinshazhou Hospital of Guangzhou University of Chinese Medicine emphasizes that cholangiocarcinoma is difficult to diagnose and carries a poor prognosis, posing a major threat to health. Early diagnosis can substantially increase curative opportunities and improve quality of life. High-risk individuals should remain vigilant, undergo regular screening, and seek prompt medical evaluation when suspicious symptoms occur to achieve early diagnosis and timely treatment.
1. Clinical presentation assessment
Common manifestations include jaundice, pruritus, clay-colored stools, right upper quadrant pain, and weight loss; alkaline phosphatase is often elevated in advanced disease.
2. Serologic testing
Liver function tests may show elevated bilirubin. CA19-9 and CEA are basic screening markers, and emerging biomarkers are under investigation.
3. Ultrasonography
Ultrasound is the first-line screening tool, demonstrating bile duct dilatation and obstruction. It can guide biopsy, but may be limited by bowel gas.
4. CT and MRI
Contrast-enhanced CT evaluates local invasion. MRI with MRCP noninvasively visualizes the biliary tree and supports staging and treatment planning.
5. Direct cholangiography
PTC delineates intrahepatic bile ducts, whereas ERCP visualizes distal ducts. Tissue sampling for histopathology can be obtained, and combined approaches improve diagnostic yield.
6. Endoscopic ultrasonography
EUS provides high-resolution imaging of the bile duct and enables EUS-guided fine-needle aspiration/biopsy to improve diagnostic accuracy for early lesions.
7. Molecular biomarker testing
Alterations such as FGFR2 and IDH1/2 are relatively common and may serve as therapeutic targets; liquid biopsy offers an emerging direction.
8. Pathological examination
Histopathology is the gold standard. Intraoperative frozen section can confirm negative margins, and tumors are classified by degree of differentiation.
Jinshazhou Hospital of Guangzhou University of Chinese Medicine emphasizes that cholangiocarcinoma is difficult to diagnose and carries a poor prognosis, posing a major threat to health. Early diagnosis can substantially increase curative opportunities and improve quality of life. High-risk individuals should remain vigilant, undergo regular screening, and seek prompt medical evaluation when suspicious symptoms occur to achieve early diagnosis and timely treatment.